{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 17:36:49", "close_timestamp": 1637516209577, "created": "21/11/2021 17:36:49", "department": "Institute of Management Studies", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "45a30c45-6580-46fd-a43b-34d8d8823d0c", "open_date_time": "2021-10-21 17:31:44", "open_timestamp": 1637515904557, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Ivermectin, an FDA-approved drug, is found to be able to significantly reduce the viral RNA within 24 hours, as shown in a study. However, more trials are needed in order to find the right amount that is safe for human consumption, and still be effective against COVID-19.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 305020, "what": "Ivermectin being able to kill COVID-19 virus", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Dr Kylie Wagstaff", "why": "An already approved drug that can kill the virus and end the pandemic sooner"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 17:24:45", "close_timestamp": 1637515485724, "created": "21/11/2021 17:24:45", "department": "Institute of Management Studies", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "54a30c35-c716-4a29-a4a1-fe8b1d12364e", "open_date_time": "2021-10-21 17:19:33", "open_timestamp": 1637515173167, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "There are a few challenges regarding the Novavax' COVID-19 vaccine. According to the data by Globaldata, in trials in Mexico and India, the efficacy of the vaccine is not high for the Alpha and Beta strains.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 312557, "what": "Challenges expected for Novavax' COVID-19 vaccine in USA", "when_happened": "few_month_ago", "where_location": "America", "who": "Nasdaq, Operation Warp Speed, Globaldata, Novavax", "why": "Inform public about the potential issues of the Novavax' COVID-19 vaccine"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 17:19:20", "close_timestamp": 1637515160644, "created": "21/11/2021 17:19:22", "department": "Institute of Management Studies", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "146f581a-0bc7-4b8b-9cce-4e705c254775", "open_date_time": "2021-10-21 17:11:52", "open_timestamp": 1637514712103, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "After months of the pandemic and using vaccines to prevent the coronavirus, a new medicine has been researched to fight the virus. It has been approved by the Australian government and they are urging GPs urged to prescribe ivermectin triple therapy to fight COVID-19.", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 448541, "what": "Finding a new cure or vaccine for coronavirus and it is to use therapy", "when_happened": "current_month", "where_location": "Australia", "who": "Australians, Australian government", "why": "A new way to cure or prevent coronavirus"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 17:31:37", "close_timestamp": 1637515897212, "created": "21/11/2021 17:31:39", "department": "Institute of Management Studies", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "316e6f87-cc1a-4961-87b4-bf34bd4c8a93", "open_date_time": "2021-10-21 17:24:51", "open_timestamp": 1637515491876, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan has approved the usage of Ronapreve and the domestic supply is secured for 2021. Ronapreve Ronapreve is able to reduce the risk of hospitalization or death (in the clinical trials). Apart from Japan, other countries are also using it. Ronapreve is also effective for the multiple variants including Delta variant in non-clinical studies.", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 405336, "what": "Ronapreve being approved in Japan and will be set for usage in 2021", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Roche", "why": "Ronapreve is able to reduce the risk of hospitalization or death and is effective for the multiple variants including Delta variant in non-clinical studies"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 18:29:51", "close_timestamp": 1637519391689, "created": "21/11/2021 18:29:53", "department": "Institute of Management Studies", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "ed80ba60-ca79-42aa-bd9e-aef1287503a2", "open_date_time": "2021-10-21 18:6:19", "open_timestamp": 1637517979954, "summary": "The Pfizer/BioNTech vaccine was approved to be used by adults in December 2020. To ensure that the vaccine can cover younger people, they are developing the shot to reach younger and more vulnerable demographics.\r\n\r\nThe trials done by Pfizer/BioNTech has found better efficacy for patients aged 12 to 15 years as compared to  those 16 to 25 years. In fact, Canada and the FDA has approved the usage of the Pfizer/BioNTech vaccine for 12 to 15 year old.\r\n\r\nPfizer has also confirmed that it intends to submit for US authorisation for the vaccine to be used in younger children and toddlers in September, and for infants by the end of the year.\r\n\r\nThe shelf-life has been increased to 31 days. This will help improve the storage, making it possible to cover more health facilities, ensuring that more people can be vaccinated against the coronavirus.\r\n\r\nThe Pfizer/BioNTech vaccine is also effective against the \"Indian\" and the \"Brazillian\" variant, and that the immunity will  continue to build over time.", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 1411735}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_13", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-21 18:4:32", "close_timestamp": 1637517872478, "created": "21/11/2021 18:04:34", "department": "Institute of Management Studies", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-21", "gender": "female", "id": "b23b2b52-cfec-42ee-9c91-6f8e8c31e06c", "open_date_time": "2021-10-21 17:36:57", "open_timestamp": 1637516217617, "summary": "Doubts about the Astrazeneca vaccine (by AstraZeneca) have rose after some European countries suspended the usage of the Astrazeneca vaccine and when AstraZeneca revised its data. The suspension happened because of the reports about potential side effects, such as blood clotting, low blood platelets and bleeding, which even led to death.\r\n\r\nFurther studies are conducted and the benefits of the Astrazeneca vaccine still outweighs the loss as the side effects are considered to only happen in very rare cases. There are also positive outcomes from the American trial - the Astrazeneca vaccine is 79% effective at preventing symptomatic disease and 100% effective at preventing severe disease and hospitalisation.\r\n\r\nHowever, when compared to other vaccines, the Astrazeneca vaccine less effective - it is only 60% effective against the \"Indian\" strain two weeks after the second dosage while Pfizer is 88% effective. The Astrazeneca vaccine also takes a longer time to reach maximum effectiveness.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 1654861}}}